Haddadin Yezan Munther's Form 4 filing
Outlook Therapeutics, Inc. (OTLK) · filed Mar 29, 2024
- Accession no.
- 0001415889-24-009394
- Filed
- Mar 29, 2024
- Trade date
- Mar 28, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market purchases total $22.2K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Haddadin Yezan MuntherCIK 0001718004 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 28, 2024 | Common Stock | PPurchaseAcquired | +1,881.71 | $11.82 | +$22,241.81 | 5,048.71 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.